

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/7360112>

# A Bromoenol Lactone Suicide Substrate Inactivates Group VIA Phospholipase A<sub>2</sub> by Generating a Diffusible Bromomethyl Keto Acid That Alkylates Cysteine Thiols †

ARTICLE in BIOCHEMISTRY · FEBRUARY 2006

Impact Factor: 3.02 · DOI: 10.1021/bi052065q · Source: PubMed

CITATIONS

42

READS

24

5 AUTHORS, INCLUDING:



**Sasanka Ramanadham**

Autonomous University of Barcelona

112 PUBLICATIONS 3,679 CITATIONS

SEE PROFILE



**Fong-Fu Hsu**

Washington University in St. Louis

187 PUBLICATIONS 8,538 CITATIONS

SEE PROFILE



**John Turk**

Washington University in St. Louis

286 PUBLICATIONS 12,616 CITATIONS

SEE PROFILE

Published in final edited form as:

Biochemistry. 2006 January 24; 45(3): 1061–1073.

# A Bromoenol Lactone Suicide Substrate Inactivates Group VIA Phospholipase A<sub>2</sub> by Generating a Diffusible Bromomethyl Keto Acid That Alkylates Cysteine Thiols<sup>†</sup>

Haowei Song, Sasanka Ramanadham, Shunzhong Bao, Fong-Fu Hsu, and John Turk<sup>\*</sup>

Medicine Department Mass Spectrometry Facility, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110

## Abstract

Phospholipases A<sub>2</sub> (PLA<sub>2</sub>) comprise a superfamily of enzymes that hydrolyze phospholipids to a free fatty acid, e.g., arachidonate, and a 2-lysophospholipid. Dissecting their individual functions has relied in large part on pharmacological inhibitors that discriminate among PLA<sub>2</sub>. Group VIA PLA<sub>2</sub> (iPLA<sub>2</sub>β) has a GTSTG serine lipase consensus sequence, and studies with a bromoenol lactone (BEL) suicide substrate inhibitor have been taken to suggest that iPLA<sub>2</sub>β participates in a wide variety of biological processes. Such conclusions presume inhibitor specificity. Inhibition by BEL requires its hydrolysis by and results in uncharacterized covalent modification(s) of iPLA<sub>2</sub>β. We performed mass spectrometric analyses of proteolytic digests of BEL-treated iPLA<sub>2</sub>β to identify modifications associated with loss of activity. The GTSTG active site and large flanking regions of sequence are not modified by BEL treatment, but most iPLA<sub>2</sub>β Cys residues are alkylated at various BEL concentrations to form a thioether linkage to a BEL keto acid hydrolysis product. Synthetic Cys-containing peptides are alkylated when incubated with iPLA<sub>2</sub>β and BEL, which reflects iPLA<sub>2</sub>β-catalyzed BEL hydrolysis to a diffusible bromomethyl keto acid product that reacts with distant thiols. The BEL concentration dependence of Cys<sup>651</sup> alkylation closely parallels that of loss of iPLA<sub>2</sub>β activity. No amino acid residues other than Cys were found to be modified, suggesting that Cys alkylation is the covalent modification of iPLA<sub>2</sub>β responsible for loss of activity, and the alkylating species appears to be a diffusible hydrolysis product of BEL rather than a tethered acyl-enzyme intermediate.

Phospholipases A<sub>2</sub> (PLA<sub>2</sub>)<sup>1</sup> catalyze hydrolysis of the *sn*-2 fatty acid substituent from glycerophospholipid substrates to yield a free fatty acid, e.g., arachidonic acid, and a 2-lysophospholipid that have intrinsic mediator activities and are precursors of other mediators, including prostaglandins, thromboxanes, leukotrienes, and platelet activating factor (PAF) (1–5). Mammalian PLA<sub>2</sub>s include low molecular weight secretory PLA<sub>2</sub> (sPLA<sub>2</sub>) that requires millimolar [Ca<sup>2+</sup>] for catalysis and affects inflammation and other processes and the PAF-acetylhydrolase PLA<sub>2</sub> family (3). Of group IV cytosolic PLA<sub>2</sub> (cPLA<sub>2</sub>) family members (3), cPLA<sub>2</sub>α prefers substrates with *sn*-2 arachidonoyl residues, associates with its substrates in membranes upon rises in cytosolic [Ca<sup>2+</sup>], and is also regulated by phosphorylation (6). There are several other members of the cPLA<sub>2</sub> family that arise from separate genes (7–10).

<sup>†</sup>This work was supported by U.S. Public Health Service Grants R37-DK34388, RO1-69455, P01-HL57278, P41-RR00954, P60-DK20579, and P30-DK56341.

<sup>\*</sup> To whom correspondence should be addressed: telephone, 314-362-8190; fax, 314-362-8188; e-mail, jturk@wustl.edu

<sup>1</sup>Abbreviations: BEL, bromoenol lactone suicide substrate; BSA, bovine serum albumin; CAD, collisionally activated dissociation; ESI, electrospray ionization; HBSS, Hank's balanced salt solution; iPLA<sub>2</sub>β, group VIA phospholipase A<sub>2</sub>; kDa, kilodaltons; KRB, Krebs–Ringer bicarbonate buffer; MEM, minimal essential medium; MS, mass spectrometry; MS/MS, tandem mass spectrometry; Cap-LC, capillary high-performance liquid chromatography; PAGE, polyacrylamide gel electrophoresis; PAPH, phosphatidate phosphohydrolase; PLA<sub>2</sub>, phospholipase A<sub>2</sub>; RP-HPLC, reverse-phase high-performance liquid chromatography; RT, reverse transcriptase; SDS, sodium dodecyl sulfate; BMKA, bromomethyl keto acid.

The group VI PLA<sub>2</sub> (iPLA<sub>2</sub>) enzymes (3,4,11–14) do not require Ca<sup>2+</sup> for catalysis and are inhibited by a bromoenol lactone (BEL) suicide substrate that does not inhibit sPLA<sub>2</sub> or cPLA<sub>2</sub> at similar concentrations (15–18). Group VIA PLA<sub>2</sub> (iPLA<sub>2</sub>β) resides in the cytoplasm of resting cells, but group VIB PLA<sub>2</sub> (iPLA<sub>2</sub>γ) contains a peroxisomal targeting sequence and is membrane-associated (19–22). These enzymes belong to a larger class of serine lipases that are encoded by multiple genes (23,24). The iPLA<sub>2</sub>β enzymes cloned from various species are 84–88 kDa proteins that contain a GX SXG lipase consensus sequence and eight stretches of a repetitive motif homologous to that in the protein-binding domain of ankyrin (11–13). No crystal structures of iPLA<sub>2</sub>β or other members of the group VI PLA<sub>2</sub> family have yet been determined.

Many potential biological functions have been proposed for iPLA<sub>2</sub>β (25–39), and the facts that multiple splice variants are differentially expressed among cells and form heterooligomers with distinct properties suggest that iPLA<sub>2</sub>β gene products might have multiple functions depending on cellular context (27,28). Among the roles proposed for iPLA<sub>2</sub>β are participation in phospholipid remodeling (26), signaling in secretion (30,31), apoptosis (32,33), vasomotor regulation (34,35), transcriptional regulation (36,37), and eicosanoid generation (38,39).

Many cells express multiple distinct PLA<sub>2</sub>s (13,17,18,40–42), and attempts to determine their individual functions have in large part relied on pharmacologic inhibitors that discriminate among PLA<sub>2</sub>. The mechanism-based iPLA<sub>2</sub> inhibitor BEL and its enantiomers (15,16,34) inhibit iPLA<sub>2</sub> at concentrations far lower than those required to inhibit sPLA<sub>2</sub> or cPLA<sub>2</sub> family members (14–18), and this property has been widely exploited to discern potential biological roles for iPLA<sub>2</sub> (25–39). BEL affects more than one target (19,23,24,43,44), however, and it was first developed as an inhibitor of serine proteases (45,46).

BEL is a substrate for the serine hydrolases chymotrypsin (45,46) and iPLA<sub>2</sub>β (15,16), and its inhibitory effects require its hydrolysis by and result in uncharacterized covalent modification (s) of those enzymes (15,16,45,46). Understanding the detailed mechanism whereby BEL inhibits iPLA<sub>2</sub>β could permit design of more selective inhibitors, and such information might also facilitate identifying other, unsuspected enzymes that are inhibited by BEL and that could account for some effects now attributed to iPLA<sub>2</sub>β inhibition.

Some haloenol lactone suicide substrates form stable acyl adducts with active site serine residues in enzymes that cause inactivation (47). BEL is proposed to interact with the chymotrypsin active site serine to form a short-lived acyl-enzyme bromomethyl ketone intermediate, which is thought to alkylate a nearby nucleophile in the enzyme, and the acylserine linkage is then hydrolyzed (45,46). A similar mechanism results in alkylation of cysteine thiol groups in enzymes (47), and the side chains of other suitably positioned amino acids could in principle be nucleophilic reactants with a halomethyl ketone intermediate. To characterize covalent modifications of iPLA<sub>2</sub>β that occur upon treatment with BEL, we have performed ESI/MS/MS analyses of proteolytic digests of purified, recombinant iPLA<sub>2</sub>β incubated with BEL.

## Experimental Procedures

### Materials

Sf9 cells and culture medium were purchased from Invitrogen (Carlsbad, CA), TALON metal affinity resin was from Clontech (Palo Alto, CA), and 1-palmitoyl-2-[<sup>14</sup>C]-linoleoyl-*sn*-glycero-3-phosphocholine (16:0/[<sup>14</sup>C]18:2-GPC) was from Amersham Biosciences (Piscataway, NJ). The cysteine-containing peptides PRCGVPDVA and RGPCRAFL were synthesized by the Washington University (St. Louis, MO) Protein and Nucleic Acid Laboratory. Other chemicals were purchased from Sigma Chemical (St. Louis, MO). Solvents

were purchased from Fisher Chemical (St. Louis, MO). PepMap HPLC columns and precolumns were obtained from LC-Packings (San Francisco, CA).

### Cloning, Expression, and Purification of Native and His-Tagged iPLA<sub>2</sub>β Proteins

*Spodoptera frugiperda* (Sf9) cells were cultured as described (48–50). For protein expression, cDNA encoding iPLA<sub>2</sub>β with a polyhistidine tag sequence at the C- or N-terminus (50) was cloned into the *EcoRI*–*SalI* site of pFastBac1 baculovirus shuttle vector (Invitrogen). Sf9 cell suspensions were infected by baculovirus, collected by centrifugation, and disrupted by sonication. His-tagged proteins were purified with a TALON metal affinity column, as described (51). Aliquots of protein solutions were analyzed by SDS–PAGE. Proteins were visualized by Coomassie staining or transfer to nylon membranes and immunoblotting, as described (51).

### Site-Directed Mutagenesis of Cys<sup>651</sup> to Ala<sup>651</sup> To Yield His-Tagged iPLA<sub>2</sub>βA<sup>651</sup> Mutant Protein

A 2.2 kb rat iPLA<sub>2</sub>β cDNA was subcloned into the vector pBluescript II SK (Stratagene) and used for mutagenesis. Substitution of Ala<sup>651</sup> for Cys<sup>651</sup> was performed with the QuickChange mutagenesis kit (Stratagene, La Jolla, CA). The sequence of the forward primer was 5'-CCC TCA AGT GCC TGT AAC CGC TGT AGA TGT CTT TCG TCC-3', and the sequence of the reverse primer was 5'-GGA CGA AAG ACA TCT ACA GCG GTT ACA GGC ACT TGA GGG-3'. The fidelity of the construct was confirmed by sequencing, and the mutated cDNA was subcloned into pFast-Bac1 vector, which was used to prepare recombinant baculovirus containing the mutant construct as an insert. The His-tagged iPLA<sub>2</sub>βA<sup>651</sup> mutant protein was expressed in Sf9 cells and purified by immobilized metal affinity chromatography, as described above.

### Incubation of Recombinant His-Tagged iPLA<sub>2</sub>β or His-Tagged iPLA<sub>2</sub>βA<sup>651</sup> with BEL, Filtration, and On-Filter Proteolytic Digestion

A solution (100 μL, 0.2 μg/μL in 200 mM imidazole and 50 mM NaCl buffer, pH 7.8) of recombinant, purified His-tagged iPLA<sub>2</sub>β or His-tagged iPLA<sub>2</sub>βA<sup>651</sup> was incubated (10 min, 37 °C) with various concentrations of BEL (0, 0.5, 1, 2, 5, 10, or 20 μM) added in ethanol (2 μL). An aliquot (10 μL) was removed to measure iPLA<sub>2</sub>β activity, and another (40 μL) was removed to measure free cysteine content. The remainder (50 μL) was processed for MS analysis by centrifugation through a YM-50 Microcon filter (Millipore, Billerica, MA) according to the manufacturer's instructions to collect iPLA<sub>2</sub>β protein and remove BEL-containing solution. The filter was then washed three times with 25 mM NH<sub>4</sub>HCO<sub>3</sub> to remove residual salt and BEL, and a solution (50 μL, 20 ng/μL) of sequencing grade protease was added to the filter. Proteases used included modified trypsin (Promega Corp., Madison, WI) or modified glutamic C endopeptidase (Princeton Separations, Adelphia, NJ). The filter was gently agitated to cause the protease solution to spread over its entire surface. After incubation (6–12 h, 37 °C), the digestion mixture was centrifuged. The aqueous solution was transferred to an Eppendorf tube and adjusted to pH 2 with 0.5% formic acid for further analysis by MS or LC/MS/MS.

### Assay of iPLA<sub>2</sub>β or His-Tagged iPLA<sub>2</sub>βA<sup>651</sup> Enzymatic Activity

Ca<sup>2+</sup>-independent PLA<sub>2</sub> enzymatic activity was assayed after ethanolic injection of the substrate 1-palmitoyl-2-[<sup>14</sup>C]linoleoyl-*sn*-glycero-3-phosphocholine in assay buffer (40 mM Tris, pH 7.5, 5 mM EGTA) by monitoring release of [<sup>14</sup>C]linoleate, as described (52).

### Spectrophotometric Quantitation of Free Thiol Content

Free thiol content of iPLA<sub>2</sub> $\beta$  was determined with Ellman's reagent (DTNB) from Molecular Probes (Eugene, OR) according to the manufacturer's instructions. DTNB was dissolved in DMSO and added (final concentration of 100 mM) to the iPLA<sub>2</sub> $\beta$  solution. After incubation (5 min, room temperature), thiol concentrations in the samples were determined from measurements of absorbance at 412 nm on a Titertek Multiskan MCC/340 microplate reader (ICN Biomedicals, Aurora, OH) with reference to a standard curve prepared with varied concentrations of L-cysteine.

### Mass Spectrometric Determination of Relative Free Cysteine Thiol Content

Relative free cysteine thiol content among samples was also estimated from mass spectrometric data by quantitative determination of the relative abundance of the cysteine-containing peptide in untreated preparations of iPLA<sub>2</sub> $\beta$  and in BEL-treated samples using the multiple normalization method of Steen et al. (53). The unmodified peptides used for normalization were selected by relative quantitative analyses that indicated little difference in their abundance in BEL-treated vs control iPLA<sub>2</sub> $\beta$  digests. Peptides from iPLA<sub>2</sub> $\beta$  that were routinely observed in proteolytic digests of both BEL-treated and untreated iPLA<sub>2</sub> $\beta$  and that were never observed in modified form were grouped. Each of these peptides was quantitated relative to all of the other unmodified peptides. Peptides with a relative quantitation value close to 1.0 were selected as members of the set of unmodified peptides to which the relative abundances of other peptides were compared. Members of this set of peptides included <sup>582</sup>SSGAPTYFRPNGR<sup>595</sup>, <sup>538</sup>QPAELHLFR<sup>546</sup>, <sup>596</sup>FLDGGLLANNPTLDAMT EIHEYNQDMIR<sup>623</sup>, <sup>38</sup>VREEGQLILLQNASNR<sup>53</sup>, <sup>396</sup>QLQDLMPVSR<sup>405</sup>, and <sup>7</sup>LVNTLSSVTNLFSPFR<sup>23</sup>.

### MALDI/TOF Mass Spectrometry

MALDI/TOF mass spectra were acquired with a Voyager DE STR instrument (Applied Biosystems, Foster City, CA), as described (51). For peptide analyses, a saturated solution of 3,5-dimethoxy-4-hydroxycinnamic acid in 50% acetonitrile was used as the matrix. For protein analyses, the matrix solution was sinapinic acid in 0.1% formic acid. The mass spectrometer was calibrated with insulin, cytochrome *c*, myoglobin, and BSA in linear mode and with trypsin autolysis peptides in reflectron mode.

### LC/ESI/MS/MS Analyses

As previously described (51), samples (0.2  $\mu$ L) were injected into a Micromass Cap-LC liquid chromatography system (Micromass, Manchester, U.K.) and concentrated on a PepMap C18 precolumn (300  $\mu$ m  $\times$  5 mm). The precolumn was then washed (3 min, 0.1% formic acid, flow rate of 30  $\mu$ L/min), and the sample was eluted onto an analytical C18 column (150 mm  $\times$  17  $\mu$ m) and analyzed with a solvent gradient from solution A (3% acetonitrile) to solution B (95% acetonitrile) containing 0.1% formic acid over 50 min at a flow rate reduced from 5  $\mu$ L/min to 200 nL/min by stream splitting.

LC eluant was introduced into the nanoflow source of a Micromass Q-TOF Micro mass spectrometer (Micromass, Manchester, U.K.). The source temperature was 80 °C, and the cone gas flow was 50 L/h. A voltage of 3.2 kV was applied to the nanoflow probe tip, and data were acquired in positive ion mode. Survey scans were integrated over 1 s, and MS/MS scans were integrated over 3 s. Switching from survey to MS/MS scan mode was performed in a data-dependent manner. The maximum MS/MS to survey scan ratio was three. The collision energy was 28 eV. Data were processed with Masslynx 3.5 software. Multi-point calibration was performed using selected fragment ions produced by CAD of Glu-fibrinopeptide B. MS/MS spectra were processed by Masslynx software to produce a peak list file, as described (51).

## Results

### His-Tagged iPLA<sub>2</sub> $\beta$ Protein Expressed from Its DNA in a BaculoVirus-Sf9 Cell System and Purified on Immobilized Metal Affinity Columns Exhibits iPLA<sub>2</sub> $\beta$ Activity That Is Inhibited by BEL

Sf9 cells infected with baculovirus containing cDNA encoding His-tagged iPLA<sub>2</sub> $\beta$  (51) were used to express the protein (Figure 1). Cytosol from these Sf9 cells was loaded onto metal affinity columns, which were then washed to remove nonadsorbed proteins. Interaction of His-tagged iPLA<sub>2</sub> $\beta$  with metal ions in the column resin was then disrupted with imidazole-containing buffers to cause desorption of His-tagged iPLA<sub>2</sub> $\beta$  protein. Eluant fractions were assayed for iPLA<sub>2</sub> $\beta$  enzymatic activity (Figure 1B), and the proteins were analyzed by SDS-PAGE and visualized by immunoblotting with an iPLA<sub>2</sub> $\beta$  antibody (Figure 1A). The activity of purified His-tagged iPLA<sub>2</sub> $\beta$  was inhibited by about 80% and nearly 100% at BEL concentrations of 5 and 20  $\mu$ M, respectively (Figure 1C). After purification by immobilized metal affinity chromatography, a nearly homogeneous preparation of His-tagged iPLA<sub>2</sub> $\beta$  was obtained, as illustrated by Coomassie blue staining of an SDS – PAGE analysis of the purified protein (Figure 1D).

### Identification of Covalently Modified Amino Acid Residues in iPLA<sub>2</sub> $\beta$ after Treatment with BEL

Purified, recombinant, His-tagged iPLA<sub>2</sub> $\beta$  was incubated without or with varied concentrations of BEL. The BEL-containing solution was then removed by centrifugal filtration to avoid inhibition of the proteases trypsin or glutamate C, which were then used to digest iPLA<sub>2</sub> $\beta$  on the filter. Proteolytic digests of BEL-treated iPLA<sub>2</sub> $\beta$  were analyzed by MALDI/TOF/MS and by LC/ESI/MS/MS. Using combined data from digests with both proteases, peptides that covered over 80% of the iPLA<sub>2</sub> $\beta$  sequence were identified.

By comparing MS/MS data from proteolytic digests of BEL-treated and untreated iPLA<sub>2</sub> $\beta$  preparations, most cysteine residues in BEL-treated iPLA<sub>2</sub> $\beta$  were found to be susceptible to covalent modification that caused peptides that contained them to exhibit a mass 254 Da greater than that for the corresponding unmodified peptides, as illustrated for peptide <sup>238</sup>VLLLCNAR<sup>245</sup> in Figure 2. The molecular mass of BEL is 317 Da, and the 254 Da mass increment of the adducts indicates that only a portion of the BEL molecule bound to the cysteine residues. The stability of adducts during LC/MS analyses indicates that the modification is covalent.

In the MS/MS spectrum of modified peptide <sup>238</sup>VLLLCNAR<sup>245</sup> (Figure 2), the y<sup>4</sup>–y<sup>8</sup> ions exhibit a 254 Da shift to higher mass values, but the y<sup>1</sup>–y<sup>3</sup> ions exhibit no shift. That indicates that Cys<sup>242</sup> is covalently modified by a BEL-derived adduct. The strong ion at 699.17 Da in Figure 2 reflects elimination of H<sub>2</sub>O from the y<sup>4</sup> ion, and this elimination is thought to occur from the BEL-derived moiety in the cysteine adduct. Similar losses of H<sub>2</sub>O from ions containing cysteine adducts were observed in MS/MS spectra of other modified peptides (data not shown). Evidence for modification of no amino acid residue other than cysteine was found in any of the spectra of peptides from proteolytic digests of BEL-treated iPLA<sub>2</sub> $\beta$  preparations, despite the fact that peptides representing over 80% of the iPLA<sub>2</sub> $\beta$  sequence were identified in such analyses.

Not every cysteine residue in the iPLA<sub>2</sub> $\beta$  sequence was found to be susceptible to BEL-induced modification. For example, no peptide containing a modified Cys<sup>428</sup> was observed, despite the fact that the unmodified peptide containing that residue was routinely identified in digests of BEL-treated iPLA<sub>2</sub> $\beta$ , as illustrated in the MS/MS spectrum of the unmodified tryptic peptide containing Cys<sup>428</sup> in Figure 3. Although Cys<sup>428</sup> is the closest Cys residue in the linear amino



acid sequence to the  $^{463}\text{GTSTG}^{467}$  catalytic center, it could well be distant from  $\text{S}^{465}$  in the three-dimensional space of the correctly folded enzyme.

### The Serine Lipase Consensus Sequence GTSTG Is Not Covalently Modified in BEL-Treated, Catalytically Inactive iPLA $_2\beta$

Another peptide that was never observed to be modified in BEL-treated iPLA $_2\beta$  preparations was that containing the  $^{463}\text{GTSTG}^{467}$  serine lipase consensus motif, even after treatment with 20  $\mu\text{M}$  BEL under conditions that eliminate all iPLA $_2\beta$  activity. Stable covalent modifications of serine residues in other enzymes by similar bromoenol lactone suicide substrates are observed (47,54), and serine residues in the catalytic centers of serine hydrolases are thought to form an acyl-enzyme intermediate with BEL (45,46).

The interaction of BEL and iPLA $_2\beta$  does not result in stable modification of its active site serine residue. Figure 4 is the MS/MS spectrum of the tryptic peptide  $^{456}\text{DLFDWVAGTSTGGI-LAILH}^{478}\text{SK}$  of iPLA $_2\beta$  that contains the  $^{463}\text{GTSTG}^{467}$  serine lipase consensus sequence, and this peptide was routinely observed in the tryptic digests of active, untreated iPLA $_2\beta$  and in those of catalytically inactive, BEL-treated iPLA $_2\beta$ . The spectrum contains all expected members of the y-ion series, and it also contains over half of the possible members of the b-ion series. Fragment ions  $y^{11}$  (1135.80 Da),  $y^{12}$  (1192.65 Da),  $y^{13}$  (1293.67 Da),  $y^{14}$  (1380.72 Da),  $y^{15}$  (1481.72 Da), and  $y^{16}$  (1538.7 Da) that define the amino acid sequence of the  $^{463}\text{GTSTG}^{467}$  lipase consensus are all detected with less than 0.20 Da deviation from theoretical  $m/z$  values. The routine observation of this peptide in digests of BEL-treated, catalytically inactive iPLA $_2\beta$  indicates that BEL does not cause stable covalent modification of  $\text{S}^{465}$  or other residues in the lipase consensus site or in the larger tryptic peptide that contains it.

A formal possibility is that a modified peptide containing the lipase consensus sequence of iPLA $_2\beta$  is formed during BEL treatment but that the resultant peptide is not recovered from proteolytic digests or identified in LC/ESI/MS/MS analyses. To evaluate this possibility, we performed relative quantitative estimates of the abundance of peptide  $^{456}\text{DLFDWVAGTSTGGI-LAILH}^{478}\text{SK}$  that contains the serine lipase consensus sequence site in untreated preparations of iPLA $_2\beta$  and in BEL-treated samples using the multiple normalization method of Steen et al. (53). In this method, the abundances of ions representing modified peptides are compared to those of ions that represent unmodified peptides. Here, the latter are those peptides not modified upon treating iPLA $_2\beta$  with BEL. Six tryptic peptides from iPLA $_2\beta$  that were routinely observed in proteolytic digests of BEL-treated and untreated iPLA $_2\beta$ , that were never observed in modified form, and that contained no cysteine residues were selected as the set of peptides that were not modified by BEL to which the abundance of modified peptides are compared (Table 1). This set of peptides represents regions of sequence from near the N-terminus, in the middle, and near the C-terminus of iPLA $_2\beta$ .

Table 1 summarizes raw and normalized intensity data for that set of reference peptides and for peptides to which they were compared in untreated and BEL-treated preparations of iPLA $_2\beta$ . One peptide that was compared to the set of unmodified reference peptides is  $^{456}\text{DLFDWVAGTSTGGI-LAILH}^{478}\text{SK}$ , which contains the  $^{463}\text{GTSTG}^{467}$  serine lipase consensus. The relative abundance of that peptide in tryptic digests of BEL-treated vs untreated iPLA $_2\beta$  preparations is estimated to be  $0.90 \pm 0.10$ , which indicates that this peptide is nearly equally abundant in untreated and BEL-treated iPLA $_2\beta$  samples. This supports the conclusion that BEL does not form a stable adduct with  $\text{S}^{465}$  or other residues in the GTSTG serine lipase consensus site as its mechanism of inactivation of iPLA $_2\beta$ .

## Facility with Which Various Cysteine Residues in the iPLA<sub>2</sub> $\beta$ Sequence Are Modified by BEL Treatment

Another peptide whose abundance was compared to that of the set of unmodified reference peptides was <sup>422</sup>S–K<sup>435</sup>. That peptide contains Cys<sup>428</sup> and, as discussed above, is unusual among cysteine-containing iPLA<sub>2</sub> $\beta$  tryptic peptides because its cysteine residue is never observed to be modified in BEL-treated iPLA<sub>2</sub> $\beta$ . The relative abundance of <sup>422</sup>S–K<sup>435</sup> between BEL-treated and untreated iPLA<sub>2</sub> $\beta$  preparations is 0.96 (Table 1), which supports the observation that Cys<sup>428</sup> is not modified by BEL treatment of iPLA<sub>2</sub> $\beta$  under conditions where many other cysteine residues do form stable adducts.

Table 2 illustrates that other cysteine residues that were not observed to be modified at any tested concentration of BEL include Cys<sup>680</sup>, Cys<sup>681</sup>, Cys<sup>143</sup>, and Cys<sup>153</sup>. These residues participate in intramolecular disulfide bonds that protect them from modification by BEL. Cys<sup>428</sup> has not been observed to participate in disulfide bonds but nonetheless has never been observed to be modified in BEL-treated iPLA<sub>2</sub> $\beta$ . We have been unable to observe a tryptic peptide that contains Cys<sup>175</sup> by MALDI/TOF/MS or LC/ESI/MS/MS, and this region of iPLA<sub>2</sub> $\beta$  sequence is among the 20% that is not represented among peptides identified in proteolytic digests.

Aside from the above exceptions, most other iPLA<sub>2</sub> $\beta$  cysteine residues were observed to be modified by BEL treatment, although some are modified only at rather high BEL concentrations (Table 2). Cys<sup>135</sup>, Cys<sup>243</sup>, and Cys<sup>651</sup> are modified at BEL concentrations as low as 0.5  $\mu$ M, while Cys<sup>697</sup> is not modified at a BEL concentration of 10  $\mu$ M but is modified at 20  $\mu$ M BEL. Cys<sup>247</sup> and Cys<sup>560</sup> are modified at 10  $\mu$ M but not 5  $\mu$ M BEL. Cys<sup>309</sup> is modified at 5  $\mu$ M but not at 2  $\mu$ M BEL. Cys<sup>333</sup> is modified at 2  $\mu$ M but not at 1  $\mu$ M BEL. Cys<sup>144</sup>, Cys<sup>229</sup>, and Cys<sup>268</sup> are modified at 1  $\mu$ M but not at 0.5  $\mu$ M BEL. There is thus a wide range of sensitivities to modification by various concentrations of BEL among different iPLA<sub>2</sub> $\beta$  cysteine residues, and the most sensitive is Cys<sup>651</sup>, 20% of which is modified at 0.5  $\mu$ M BEL. The data in Table 2 must be evaluated with the caveat that the concentration of BEL required to yield detectable amounts of a modified peptide will depend on analytic sensitivity, which could differ among different peptides and perhaps between nonmodified and modified peptide pairs.

## BEL Concentration Dependence of Cysteine Modification and of iPLA<sub>2</sub> $\beta$ Inactivation

Figure 5 illustrates the BEL concentration dependence of iPLA<sub>2</sub> $\beta$  catalytic inactivation and loss of free cysteine thiol groups as estimated by a spectrophotometric assay with DTNB reagent (Figure 5A) and by mass spectrometric measurements of the relative abundance of unmodified and modified cysteine-containing peptides from tryptic digests of untreated and BEL-treated iPLA<sub>2</sub> $\beta$  (Figure 5B–D). The cysteine free thiol content measured by spectrophotometry declined more than did iPLA<sub>2</sub> $\beta$  activity at low BEL concentrations but declined less than did iPLA<sub>2</sub> $\beta$  activity at higher BEL concentrations (Figure 5A). This might indicate that modifying many cysteines does not affect catalytic activity, but when one or a small number of critical cysteine residues is modified, activity falls precipitously as a steeper function of increasing BEL concentration than does protein bulk thiol content.

There is a closer correspondence between decline in activity and decline in unmodified cysteine content estimated mass spectrometrically. Of all the iPLA<sub>2</sub> $\beta$  cysteine residues that were observed to be modified, the BEL concentration dependence of the decline of unmodified Cys<sup>651</sup> most closely follows the decline of iPLA<sub>2</sub> $\beta$  activity (Figure 5B). Both curves in Figure 5B have an IC<sub>50</sub> value of about 3.5  $\mu$ M BEL, suggesting that modification of Cys<sup>651</sup> might be involved in iPLA<sub>2</sub> $\beta$  inactivation.



### BEL Concentration Dependence of Inactivation of an iPLA<sub>2</sub>β Mutant Protein in Which Cys<sup>651</sup> Is Replaced by Ala<sup>651</sup>

To evaluate further the possibility that alkylation of Cys<sup>651</sup> might play a role in iPLA<sub>2</sub>β inactivation by BEL, that residue was replaced with Ala<sup>651</sup>, which has no thiol group that can be alkylated, by site-directed mutagenesis. The His-tagged mutant iPLA<sub>2</sub>βA<sup>651</sup> protein was expressed in a baculovirus–Sf9 cell system and purified by immobilized metal affinity chromatography, in the manner illustrated for His-tagged native iPLA<sub>2</sub>β in Figure 1. The iPLA<sub>2</sub>β catalytic activity and the BEL concentration dependence of inactivation of the iPLA<sub>2</sub>βA<sup>651</sup> mutant protein were then compared to native iPLA<sub>2</sub>β, as illustrated in Figure 6.

The iPLA<sub>2</sub>βA<sup>651</sup> mutant retained essentially full catalytic activity but was less sensitive to inhibition by BEL than was native iPLA<sub>2</sub>β (Figure 6). At a BEL concentration of 1 μM, for example, the iPLA<sub>2</sub>βA<sup>651</sup> mutant protein exhibited about 60% of control activity, but native iPLA<sub>2</sub>β retained only about 20% of control activity. Although higher concentrations of BEL were required to inhibit iPLA<sub>2</sub>βA<sup>651</sup> than to inhibit native iPLA<sub>2</sub>β, the mutant enzyme could be inactivated completely at sufficiently high BEL concentrations. These findings suggest that alkylation of Cys<sup>651</sup> might be sufficient to inactivate iPLA<sub>2</sub>β but that Cys<sup>651</sup> alkylation is not necessary iPLA<sub>2</sub>β inactivation, which can also result from modification of other residues.

### Studies of the Mechanism of Covalent Modification of Cysteine Residues by BEL with Synthetic Cysteine-Containing Peptides

We had not anticipated our observation that numerous cysteine residues would be modified in BEL-treated iPLA<sub>2</sub>β because inactivation of chymotrypsin by BEL is reported to require covalent attachment of only a single BEL-derived moiety per enzyme molecule (45,46). Moreover, BEL is thought to inflict its inactivating covalent modification on enzymes from a tethered position as an acyl intermediate adduct with the active site serine rather than by diffusing to reach distant targets (15,16,45,46).

This would seem to constrain its site of action to a relatively small volume around the active site, which makes our observation that multiple cysteine residues throughout the iPLA<sub>2</sub>β sequence are modified by BEL seem puzzling. To test the possibility that a diffusible species derived from the action of iPLA<sub>2</sub>β on BEL mediates cysteine alkylation, two peptides (RGPCRAFL and PRCGVDPVA) that contain a free cysteine residue were synthesized and incubated with BEL in the presence or absence of iPLA<sub>2</sub>β.

Figure 7 illustrates that when these model peptides were incubated with BEL but not iPLA<sub>2</sub>β, only ions attributable to the unmodified peptides were observed in their MALDI/TOF mass spectra. The [M + H]<sup>+</sup> ion of peptide RGPCRAFL is observed at the expected *m/z* 919.59 Da (Figure 7A) and that for peptide PRCGVDPVA at the expected *m/z* 913.67 Da (Figure 7B). This indicates that BEL cannot directly modify the peptides.

When the peptides were incubated with the same concentration of BEL in the presence of iPLA<sub>2</sub>β, adduct ions were observed for each peptide that reflected an increment in mass of 254 daltons, as expected for the previously observed cysteine adduct with a BEL-derived moiety (Figure 7C,D). The [M + 254 + H]<sup>+</sup> ion for the modified peptide RGP(C-BEL)RAFL is observed at *m/z* 1173.66 (Figure 7C). Ions in this spectrum of *m/z* 1129.66 and 1155.63 reflect elimination from *m/z* 1173.66 of CO<sub>2</sub> or H<sub>2</sub>O, respectively, from the BEL-derived moiety in the Cys adduct.

Similar ions were observed in the analogous spectrum for the peptide PR(C-BEL)GVDPVA derived from incubation of the parent peptide PRCGVDPVA with BEL and iPLA<sub>2</sub>β (Figure 7D). The [M + 254 + H]<sup>+</sup> ion is observed at the expected *m/z* value of 1167.34, and losses of H<sub>2</sub>O or CO<sub>2</sub>, from that ion, yield the ions of *m/z* 1149.34 and 1123.37, respectively (Figure

7D). Figure 8 illustrates ESI/MS/MS spectra of BEL-modified peptides RGP(C-BEL)RAFL ( $m/z$  1173.66) and PR(C-BEL)GVPDVA ( $m/z$  1167.34), and the observed fragment ion series demonstrate that cysteine is the modified amino acid in peptides incubated with BEL and iPLA<sub>2</sub> $\beta$ . The observations in Figures 7 and 8 demonstrate that catalytic action of iPLA<sub>2</sub> $\beta$  on BEL is required to generate modified peptides from their parents.

Figure 9 illustrates the BEL concentration dependence for modification of synthetic peptides in incubations with a fixed concentration of iPLA<sub>2</sub> $\beta$ . The fraction of peptide molecules modified is estimated from the intensities of ions representing modified and unmodified forms of the peptides. This fraction increases with BEL concentrations up to 10  $\mu$ M and declines at higher concentrations. This could reflect the opposing effects of production of BMKA from BEL to result in alkylation of bystander peptides but also in inactivation of iPLA<sub>2</sub> $\beta$ . When all iPLA<sub>2</sub> $\beta$  activity is eliminated, it can catalyze no further hydrolysis of BEL to the BMKA that alkylates bystander cysteine-containing peptides. Because iPLA<sub>2</sub> $\beta$  is the source of BMKA, the local concentration of that species in the vicinity of iPLA<sub>2</sub> $\beta$  could exceed that in the vicinity of bystander peptides, and this may result in its preferential alkylation at higher BEL concentrations.

The observations in Figures 7–9 establish that alkylation of cysteine-containing peptides in incubations of BEL and iPLA<sub>2</sub> $\beta$  requires the catalytic action of iPLA<sub>2</sub> $\beta$  to generate a diffusible reactive species that can travel out of the active site to alkylate cysteine residues at distant sites, and this could also cause modification of cysteine residues in iPLA<sub>2</sub> $\beta$ .

### Protection of Cysteine Residues in iPLA<sub>2</sub> $\beta$ from Modification upon Hydrolysis of BEL by Including Dithiothreitol in the Incubation Medium

To test the possibility that a diffusible alkylating species generated by iPLA<sub>2</sub> $\beta$ -catalyzed BEL hydrolysis is responsible for modification of cysteine residues, the effect of including the scavenging nucleophile dithiothreitol (DTT) in the incubation mixtures was examined. Figure 10A illustrates that DTT suppresses alkylation of cysteine residues that otherwise occurs upon incubation of iPLA<sub>2</sub> $\beta$  with BEL, and DTT also attenuates catalytic inactivation of iPLA<sub>2</sub> $\beta$ . This supports the conclusion that modification of iPLA<sub>2</sub> $\beta$  cysteine residues is mediated by a diffusible alkylating species that is accessible to and reacts with DTT in the incubation medium. Interestingly, most modifiable cysteine residues in iPLA<sub>2</sub> $\beta$  were completely protected from BEL-induced modification at DTT concentrations between 0.2 and 1 mM. In contrast, Cys<sup>651</sup> was protected from modification to a lesser extent at such DTT concentrations, and 5 mM DTT was required for complete protection. This residue thus could be less accessible to DTT-containing bulk solvent and buried within the folded enzyme, perhaps topologically close to the active site.

## Discussion

Previous studies of covalent modification and catalytic inactivation of serine hydrolases by BEL and related haloenol lactones suggest that catalytic action of the hydrolase on BEL is required for inactivation and that covalent attachment of a BEL-derived moiety to the enzyme occurs (15,16,45,46). Our results demonstrate that these features of the interaction of serine hydrolases and BEL pertain to recombinant iPLA<sub>2</sub> $\beta$  and point to the unexpected conclusions that cysteine alkylation could be the inactivating covalent modification and could be mediated by a diffusible species.

The model of inhibition of serine hydrolases, e.g., chymotrypsin, is that BEL is a suicide substrate that forms an acyl-enzyme intermediate with the active site serine hydroxyl. This involves opening the lactone ring to yield a bromomethyl keto-substituted carboxylic acid ester. The bromomethyl keto moiety then alkylates a nearby nucleophile in a reaction that also

generates HBr (45,46). The acyl linkage between the BEL residue and the active site serine hydroxyl is then hydrolyzed to regenerate an unsubstituted active site serine and an alkyl keto acid residue of BEL that is covalently bound to the enzyme (45,46). The initial acyl-enzyme structure formed between a serine hydrolase and an activated enol lactone inhibitor is stable in some cases, however, and the active site serine remains acylated (54). Our findings clearly indicate that this is not the case for iPLA<sub>2</sub> $\beta$  because the active site S<sup>465</sup> is not modified upon incubation with BEL under conditions where complete catalytic inactivation occurs.

Candidate nucleophiles that might react with the bromomethyl moiety derived from BEL include OH, SH, and NH groups in the side chains of several amino acids. Covalent linkages with haloenol lactone suicide substrates have been reported to occur with serine and cysteine (47,54) and perhaps with histidine (46) side chains. In the case of iPLA<sub>2</sub> $\beta$ , cysteine is the only modified amino acid residue that we detect after incubation with BEL under conditions in which complete catalytic activation occurs and 80% overall sequence coverage is obtained in MS analyses of iPLA<sub>2</sub> $\beta$  peptides in proteolytic digests.

In the <sup>351</sup>T–P<sup>550</sup> region of the linear amino acid sequence flanking the active site S<sup>465</sup>, combined data from trypsin and Glu-C digests of iPLA<sub>2</sub> $\beta$  yield over 90% sequence coverage (Figure 11), and no modified amino acid residues in that region are observed in BEL-treated, catalytically inactivated iPLA<sub>2</sub> $\beta$ . In addition, no modification of the cysteine residue closest to S<sup>465</sup> in the linear amino acid sequence (Cys<sup>428</sup>) is observed in BEL-treated iPLA<sub>2</sub> $\beta$  even under conditions where several other modified cysteine residues are observed. Proximity of amino acid residues in the linear amino acid sequence, of course, need not reflect their proximity in the topologic three-dimensional space of the correctly folded enzyme. Of the covalently modified cysteine residues that we identified, the BEL concentration dependence for Cys<sup>651</sup> alkylation most closely parallels catalytic inactivation of iPLA<sub>2</sub> $\beta$ . Although Cys<sup>651</sup> is distant from the catalytic center S<sup>465</sup> in the linear amino acid sequence of iPLA<sub>2</sub> $\beta$ , it could be topologically proximate to that site in the correctly folded, catalytically active enzyme. This might cause it to be accessible to and readily alkylated by the bromomethyl keto moiety derived from BEL hydrolysis, and that alkylation could impair substrate binding or catalysis.

We believe that alkylation of cysteine residues involves the diffusible BEL hydrolysis product BMKA produced by iPLA<sub>2</sub> $\beta$  catalysis, as illustrated in Scheme 1, rather than a bromomethyl.keto moiety tethered to the active site serine. Consistent with this scheme, the mass of the cysteine adduct in peptides modified in incubations of BEL and iPLA<sub>2</sub> $\beta$  is 254 Da greater than the unmodified peptide mass. This reflects elimination of HBr (81 Da) from BEL (317 Da) and addition of H<sub>2</sub>O (18 Da) to generate the BMKA that alkylates cysteine. BMKA itself irreversibly inactivates chymotrypsin (46) and thus has sufficient intrinsic reactivity to modify nucleophilic sites in enzymes and to cause catalytic inactivation.

The fact that the alkylating species generated from BEL by iPLA<sub>2</sub> $\beta$  is diffusible rather than tethered to the active site serine is reflected by our findings that most iPLA<sub>2</sub> $\beta$  cysteine residues can be alkylated upon BEL treatment, even though a much smaller fraction of them would be expected to be accessible to a bromomethyl keto moiety tethered to S<sup>465</sup>; that cysteine residues in bystander synthetic peptides are also alkylated when incubated with BEL and iPLA<sub>2</sub> $\beta$  but not with BEL alone; and that adding DTT to the medium protects iPLA<sub>2</sub> $\beta$  cysteine residues from alkylation during incubation with BEL.

That the BEL-derived alkylating species need not always diffuse from the region near the active site, enter the bulk solution, and travel to distant sites to inhibit iPLA<sub>2</sub> is suggested by reports that under some conditions scavenging nucleophiles in the incubation medium do not prevent iPLA<sub>2</sub> inhibition by BEL, that adding BMKA itself to the incubation does not inhibit iPLA<sub>2</sub>,

and that a nearly 1:1 stoichiometry of covalently bound BEL moiety and inactivated iPLA<sub>2</sub> molecules is observed (15,16). Those studies, however, were performed before iPLA<sub>2</sub>β had been cloned and its sequence determined and before its molecular weight was known. Our studies here are the first of which we are aware to examine the mechanism of inhibition of purified, recombinant iPLA<sub>2</sub>β by BEL.

Alkylation of bystander peptides incubated with iPLA<sub>2</sub>β and BEL by the diffusible alkylating species BMKA suggests that other enzymes in the vicinity of iPLA<sub>2</sub>β exposed to BEL might be alkylated. Some alkylations could be functionally silent, as suggested by the poor correspondence between loss of bulk thiol groups and iPLA<sub>2</sub>β inactivation by BEL demonstrated in Figure 5, but other alkylations could inactivate bystander enzymes.

Our observation that cysteine is the amino acid most readily alkylated by BMKA suggests that enzymes with an active site cysteine residue might be among the most susceptible to inhibition by BEL or similar compounds. Glutathione *S*-transferase has a critical active site Cys<sup>47</sup>, and that enzyme is inactivated by a bromoenol lactone hydrolysis product by a mechanism that involves Cys<sup>47</sup> alkylation (47). Similarly, the lipid phosphatase phosphatidate phosphohydrolase 1 (PAPH-1) is one non-iPLA<sub>2</sub>β enzyme recognized to be inhibited in BEL-treated cells, and that enzyme is also inhibited by other thiol-modifying agents (43).

Inhibition of PAPH-1 accounts for some biological effects of BEL (44), and active site cysteine residues are required for catalysis by many enzymes, including other lipid phosphatases (55), protein tyrosine phosphatases (56), and serine–threonine phosphatases (57) that are involved in insulin signaling, MAP kinase signaling, and tumor suppression (55–58). Our findings suggest that BEL should be used with appropriate caution when studying such events.

#### Acknowledgements

We thank Dr. Kevin Yarasheski for stimulating discussions about the relative quantitation method; Dr. Mary Wohltmann, Alan Bohrer, Wu Jin, and Sheng Zhang for excellent technical assistance; and Jessica Jackson for assistance with the manuscript.

#### References

1. Brash AR. Arachidonic acid as a bioactive molecule. *J Clin Invest* 2001;107:1339–1345. [PubMed: 11390413]
2. Radu CG, Yang LV, Riedinger M, Au M, Witte ON. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. *Proc Natl Acad Sci USA* 2004;101:245–250. [PubMed: 14681556]
3. Six D, Dennis E. The expanding superfamily of phospholipase A<sub>2</sub> enzymes: classification and characterization. *Biochim Biophys Acta* 2000;1488:1–19. [PubMed: 11080672]
4. Ma Z, Turk J. The molecular biology of the group VIA Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub>. *Prog Nucleic Acid Res Mol Biol* 2001;67:1–33. [PubMed: 11525380]
5. Murphy RC, Fitzpatrick FA. Arachidonate related lipid mediators. *Methods Enzymol* 1990;187:1–628.
6. Gijon M, Spencer D, Kaiser A, Leslie C. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A<sub>2</sub>. *J Cell Biol* 1999;145:1219–1232. [PubMed: 10366595]
7. Underwood KW, Song C, Kriz RW, Chang XJ, Knopf JL, Lin LL. A novel calcium-independent phospholipase A<sub>2</sub>, cPLA<sub>2</sub>γ, that is prenylated and contains homology to cPLA<sub>2</sub>. *J Biol Chem* 2002;273:21926–21932. [PubMed: 9705332]
8. Pinckard RT, Strifle BA, Kramer RM, Sharp JD. Molecular cloning of two new human paralogs of 85 kDa cytosolic phospholipase A<sub>2</sub>. *J Biol Chem* 1999;274:8823–8831. [PubMed: 10085124]
9. Song C, Chang XJ, Bean KM, Proia MS, Knopf JL, Kriz RW. Molecular characterization of cytosolic phospholipase A<sub>2</sub>β. *J Biol Chem* 1999;274:17063–17067. [PubMed: 10358058]


10. Ohto T, Uozumi N, Hirabayashi T, Shimizu T. Identification of novel cytosolic phospholipase A<sub>2</sub>S, murine cPLA<sub>2</sub>δ, ε and ζ, which form a gene cluster with cPLA<sub>2</sub>β. *J Biol Chem* 2005;280:24576–24583. [PubMed: 15866882]
11. Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, Jones SS. A novel cytosolic calcium-independent phospholipase A<sub>2</sub> contains eight ankyrin motifs. *J Biol Chem* 1997;272:8567–8575. [PubMed: 9079687]
12. Balboa MA, Balsinde J, Jones S, Dennis EA. Identity between the calcium-independent phospholipase A<sub>2</sub> enzymes from P388D1 macrophages and Chinese hamster ovary cells. *J Biol Chem* 1997;272:8576–8590. [PubMed: 9079688]
13. Ma Z, Ramanadham S, Kempe K, Chi XS, Ladenson J, Turk J. Pancreatic islets express a Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. *J Biol Chem* 1997;272:11118–11127. [PubMed: 9111008]
14. Balsinde J, Dennis EA. Function and inhibition of intracellular calcium-independent phospholipase A<sub>2</sub>. *J Biol Chem* 1997;272:16069–16072. [PubMed: 9195897]
15. Hazen SL, Zupan LA, Weiss RH, Getman DP, Gross RW. Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A<sub>2</sub>. Mechanism-based discrimination between calcium-dependent and -independent phospholipases A<sub>2</sub>. *J Biol Chem* 1991;266:7227–7232. [PubMed: 2016324]
16. Zupan LA, Weiss RH, Hazen S, Parnas BL, Aston KW, Lennon PJ, Getman DP, Gross RW. Structural determinants of haloenol lactone-mediated suicide inhibition of canine myocardial calcium-independent phospholipase A<sub>2</sub>. *J Med Chem* 1993;36:95–100. [PubMed: 8421294]
17. Ma Z, Ramanadham S, Hu Z, Turk J. Cloning and expression of a type IV cytosolic phospholipase A<sub>2</sub> enzyme from a pancreatic islet cDNA library. Comparison of the expressed activity with that of the islet type VI cytosolic phospholipase A<sub>2</sub>. *Biochim Biophys Acta* 1998;1391:384–400. [PubMed: 9555100]
18. Balsinde J, Dennis EA. Distinct roles in signal transduction for each of the phospholipase A<sub>2</sub> enzymes present in P388D1 macrophages. *J Biol Chem* 1996;271:6758–6765. [PubMed: 8636097]
19. Mancuso D, Jenkins CM, Gross RW. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A<sub>2</sub>. *J Biol Chem* 2000;275:9937–9945. [PubMed: 10744668]
20. Tanaka H, Takeya R, Sumimoto H. A novel intracellular membrane-bound calcium-independent phospholipase A<sub>2</sub>. *Biochem Biophys Res Commun* 2000;272:320–326. [PubMed: 10833412]
21. Yang J, Han X, Gross RW. Identification of hepatic peroxisomal phospholipase A<sub>2</sub> and characterization of arachidonic acid-containing choline glycerophospholipids in hepatic peroxisomes. *FEBS Lett* 2003;546:247–250. [PubMed: 12832049]
22. Mancuso DJ, Jenkins CM, Sims HF, Cohen JM, Yang J, Gross RW. Complex transcriptional and translational regulation of iPLA<sub>2</sub>γ resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localization. *Eur J Biochem* 2004;271:4709–4724. [PubMed: 15606758]
23. Van TM, Atkins J, Li Y, Glynn P. Human neuropathy target esterase catalyzes hydrolysis of membrane lipids. *J Biol Chem* 2002;277:20942–20948. [PubMed: 11927584]
24. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purifications of three novel human calcium-independent phospholipase A<sub>2</sub> family members possessing triacylglycerol lipase and acylglycerol transacylase activities. *J Biol Chem* 2004;279:48968–48975. [PubMed: 15364929]
25. Balsinde J, Bianco ID, Ackerman EJ, Conde-Friebos K, Dennis EA. Inhibition of calcium-independent phospholipase A<sub>2</sub> prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. *Proc Natl Acad Sci USA* 1995;92:8527–8531. [PubMed: 7667324]
26. Baburina I, Jackowski S. Cellular responses to excess phospholipid. *J Biol Chem* 1999;274:9400–9408. [PubMed: 10092620]
27. Larsson PKA, Claesson HE, Kennedy BP. Multiple splice variants of the human calcium-independent phospholipase A<sub>2</sub> and their effect on enzyme activity. *J Biol Chem* 1998;273:207–214. [PubMed: 9417066]




28. Ma Z, Wang X, Nowatzke W, Ramanadham S, Turk J. Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A<sub>2</sub> (iPLA<sub>2</sub>) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA<sub>2</sub> gene on chromosome 22q13.1. *J Biol Chem* 1999;274:9607–9616. [PubMed: 10092647]
29. Balboa MA, Saez Y, Balsinde J. Calcium-independent phospholipase A<sub>2</sub> is required for lysozyme secretion in U937 promonocytes. *J Immunol* 2003;170:5276–5280. [PubMed: 12734377]
30. Owada S, Larsson O, Arkhammar P, Katz AI, Chibalin AV, Berggren PO, Bertorello AM. Glucose decreases Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in pancreatic beta-cells. An effect mediated via Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> and protein kinase C-dependent phosphorylation of the alpha-subunit. *J Biol Chem* 1999;274:2000–2008. [PubMed: 9890957]
31. Ramanadham S, Song H, Hsu FF, Zhang S, Crankshaw M, Grant G, Newgard C, Turk J. Pancreatic islets and insulinoma cells express a novel isoform of group VIA phospholipase A<sub>2</sub> (iPLA<sub>2</sub>β) that participates in glucose-stimulated insulin secretion and is not produced by alternate splicing of the iPLA<sub>2</sub>β transcript. *Biochemistry* 2003;42:13929–13940. [PubMed: 14636061]
32. Atsumi GI, Murakami M, Kojima K, Hadano A, Tajima M, Kudo I. Distinct roles of two intracellular phospholipase A<sub>2</sub>s in fatty acid release in the cell death pathway. Proteolytic fragment of type IVA cytosolic phospholipase A<sub>2</sub>α inhibits stimulus-induced arachidonate release, whereas that of type VI Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> augments spontaneous fatty acid release. *J Biol Chem* 2000;275:18248–18258. [PubMed: 10747887]
33. Ramanadham S, Hsu FF, Zhang S, Jin C, Bohrer A, Ma Z, Turk J. Involvement of the group VIA phospholipase A<sub>2</sub> (iPLA<sub>2</sub>β) in endoplasmic reticulum stress-induced apoptosis in insulinoma cells. *Biochemistry* 2004;43:918–930. [PubMed: 14744135]
34. Jenkins CM, Han X, Mancuso DJ, Gross RW. Identification of calcium-independent phospholipase A<sub>2</sub>β (iPLA<sub>2</sub>β), and not iPLA<sub>2</sub>γ as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA<sub>2</sub>s. *J Biol Chem* 2002;277:32807–32814. [PubMed: 12089145]
35. Smani T, Zakharov SI, Csutora P, Leno E, Trepakova ES, Bolotina VM. A novel mechanism for the store-operated calcium influx pathway. *Nat Cell Biol* 2004;6:113–120. [PubMed: 14730314]
36. Williams SD, Ford DA. Calcium-independent phospholipase A<sub>2</sub> mediates CREB phosphorylation and c-fos expression during ischemia. *Am J Physiol* 2001;281:H168–H176.
37. Moran JM, Butler RM, McHowat J, Turk J, Wohltmann M, Gross RW, Corbett JA. Genetic and pharmacologic evidence that iPLA<sub>2</sub>β regulates virus-induced iNOS expression by macrophages. *J Biol Chem* 2005;280:28162–28168. [PubMed: 15946940]
38. Murakami M, Kambe T, Shimbara S, Kudo I. Functional coupling between various phospholipase A<sub>2</sub>s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. *J Biol Chem* 1999;274:3103–3115. [PubMed: 9915849]
39. Tay HR, Melendez AJ. FcγRI-triggered generation of arachidonic acid and eicosanoids requires iPLA<sub>2</sub> but not cPLA<sub>2</sub> in human monocytic cells. *J Biol Chem* 2004;279:22505–22513. [PubMed: 15007079]
40. Ramanadham S, Ma Z, Arita H, Zhang S, Turk J. Type IB secretory phospholipase A<sub>2</sub> is contained in the insulin secretory granules of pancreatic islet beta cells and is co-secreted with insulin upon stimulation of islets with glucose. *Biochim Biophys Acta* 1998;1390:301–312. [PubMed: 9487151]
41. Su X, Mancuso DJ, Bickel PE, Jenkins CM, Gross RW. Small interfering RNA knockdown of calcium-independent phospholipases A<sub>2</sub>β or γ inhibits the hormone-induced differentiation of 3T3-L1 preadipocytes. *J Biol Chem* 2004;279:21740–21748. [PubMed: 15024020]
42. Shrai Y, Balsinde J, Dennis DA. Localization and functional interrelationships among cytosolic group IV, secreted group V, and Ca<sup>2+</sup>-independent group VI phospholipases A<sub>2</sub>s in P388D1 macrophages using GFP/RFP constructs. *Biochim Biophys Acta* 2005;1735:119–129. [PubMed: 15967714]
43. Balsinde J, Dennis EA. Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages. *J Biol Chem* 1996;271:31937–31941. [PubMed: 8943239]
44. Fuentes L, Perez R, Nieto ML, Balsinde J, Balboa MA. Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A<sub>2</sub>. *J Biol Chem* 2003;278:44683–44690. [PubMed: 12952946]




45. Daniels SB, Cooner E, Sofia MJ, Chakravarty PK, Katzenellenbogen JA. Haloenol lactones. Potent enzyme-activated irreversible inhibitors for  $\alpha$ -chymotrypsin. *J Biol Chem* 1983;258:15046–15053. [PubMed: 6654902]
46. Daniels SB, Katzenellenbogen JA. Halo enol lactones: studies on the mechanism of inactivation of alphachymotrypsin. *Biochemistry* 1986;25:1436–1444. [PubMed: 3964685]
47. Mitchell AE, Zheng J, Hammock BD, Bello ML, Jones AD. Structural and functional consequences of haloenol lactone inactivation of murine and human glutathione S-transferase. *Biochemistry* 1998;37:6752–6759. [PubMed: 9578559]
48. Nowatzke W, Ramanadham S, Hsu FF, Ma Z, Bohrer A, Turk J. Mass spectrometric evidence that agents that cause loss of  $\text{Ca}^{2+}$  from intracellular compartments induce hydrolysis of arachidonic acid from pancreatic islet membrane phospholipids by a mechanism that does not require a rise in cytosolic  $\text{Ca}^{2+}$  concentration. *Endocrinology* 1998;139:4073–4085. [PubMed: 9751485]
49. O'Reilly, DR.; Miller, LK.; Luckow, VA. *Baculovirus Expression Vector: A Laboratory Manual*. W. H. Freeman and Co.; New York: 1992.
50. Bao S, Jin C, Zhang S, Turk J, Ma Z, Ramanadham S. Tracking iPLA $_2$  $\beta$  movements in response to stimulation with insulin secretagogues in INS-1 Cells. *Diabetes* 2004;53:S186–S189. [PubMed: 14749286]
51. Song H, Hecimovic S, Goate A, Hsu FF, Bao S, Vidavsky I, Ramanadham S, Turk J. Characterization of N-terminal processing of group VIA phospholipase A $_2$  and of potential cleavage sites of amyloid precursor protein constructs by automated identification of signature peptides in LC/MS/MS analyses of proteolytic digests. *J Am Soc Mass Spectrom* 2004;12:1780–1793. [PubMed: 15589755]
52. Gross RW, Ramanadham S, Kruszka KK, Han X, Turk J. Rat and human pancreatic islet cells contain a calcium ion independent phospholipase A $_2$  activity selective for hydrolysis of arachidonate, which is stimulated by adenosine triphosphate and is specifically localized to islet  $\beta$ -cells. *Biochemistry* 1993;32:327–336. [PubMed: 8418853]
53. Steen H, Jebanathirajah JA, Springer M, Kirschner MW. Stable isotope-free relative and absolute quantitation of protein phosphorylation stoichiometry by MS. *Proc Natl Acad Sci U S A* 2005;102:3948–3953. [PubMed: 15741271]
54. Baek DJ, Reed PE, Daniels SB, Katzenellenbogen JA. Alternate substrate inhibitors of an alpha-chymotrypsin: enantioselective interaction of aryl-substituted enol lactones. *Biochemistry* 1990;29:4305–4311. [PubMed: 2350538]
55. Maehama T, Dixon JE. The tumor suppressor, ptn.mmac1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* 1998;273:13375–13378. [PubMed: 9593664]
56. Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, Moller NP. Structural and evolutionary relationships among protein tyrosine phosphatases. *Mol Cell Biol* 2001;21:7117–7136. [PubMed: 11585896]
57. Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signaling. *Curr Opin Cell Biol* 2000;12:186–192. [PubMed: 10712927]
58. Goldstein BJ, Mahadev K, Wu X. Redox paradox. Insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. *Diabetes* 2005;54:311–321. [PubMed: 15677487]

**FIGURE 1.**


Expression of His-tagged iPLA<sub>2</sub>β in Sf9 cells and its purification on metal affinity columns. Cytosol from Sf9 cells infected with baculovirus containing DNA that encodes His-tagged iPLA<sub>2</sub>β was loaded onto a TALON immobilized metal affinity column (IMAC), which was then washed to remove weakly adherent proteins, and His-tagged iPLA<sub>2</sub>β was desorbed with buffer containing 200 mM imidazole. Proteins in aliquots of load (L), void (V), and elution fractions were analyzed by SDS-PAGE and immunoblotting with an iPLA<sub>2</sub>β antibody (panel A), and iPLA<sub>2</sub>β specific activity was also determined (panel B). Effects of 0, 5, and 20 μM BEL on the activity of purified, His-tagged iPLA<sub>2</sub>β recovered from the IMAC columns were also determined (panel C). Displayed values represent means ± SD (*n* = 6). The purified preparation of recombinant His-tagged iPLA<sub>2</sub>β was analyzed by SDS-PAGE with Coomassie blue staining to evaluate the purity of the protein (panel D).

**FIGURE 2.**


Tandem mass spectrum of the BEL-modified iPLA $_2\beta$  peptide  $^{238}\text{VLLLCNAR}^{245}$  produced by CAD of  $[\text{M} + 2\text{H}]^{2+}$  ( $m/z$  578.14). Purified His-tagged iPLA $_2\beta$  ( $10\ \mu\text{g}$ ) was treated with  $20\ \mu\text{M}$  BEL and digested with trypsin, and peptides in the digest were analyzed by LC/MS with data-dependent switching to MS/MS.

**FIGURE 3.**

Tandem mass spectrum of the iPLA<sub>2</sub>β tryptic peptide <sup>422</sup>SHDHLLCLDGGGVK<sup>435</sup> produced by CAD of [M + 2H]<sup>2+</sup> (m/z 725.79 Da).


**FIGURE 4.**

Tandem mass spectrum of iPLA<sub>2</sub>β tryptic peptide that contains the serine lipase consensus sequence (<sup>456</sup>DLFDWVA<sup>463</sup>GTSTG<sup>467</sup>GILALAILHSK<sup>478</sup>) produced by CAD of [M + 3H]<sup>3+</sup> (*m/z* 795.41 Da). BEL-treated, His-tagged iPLA<sub>2</sub>β was digested with trypsin, and resultant peptides were analyzed as in Figure 2.

**FIGURE 5.**


BEL concentration dependence of the decline in iPLA<sub>2</sub>β activity, free thiol content, and fraction of unmodified Cys<sup>651</sup>, Cys<sup>242</sup>, or Cys<sup>267</sup>. Purified, His-tagged iPLA<sub>2</sub>β was incubated (37 °C, 10 min) with various concentrations of BEL, and aliquots were removed for measurement of iPLA<sub>2</sub>β specific activity (closed circles, all panels), free thiol content determined by reaction with DTNB and spectrophotometry (closed squares, panel A), and fraction of unmodified Cys<sup>651</sup> (open triangles, panel B), Cys<sup>242</sup> (open diamonds, panel C), or Cys<sup>267</sup> (open circles, panel D) determined by LC/MS/MS analyses of tryptic digests. Values are expressed as a percent of those observed at a BEL concentration of zero. Mean values (±SD) are displayed (n = 6).






**FIGURE 6.**


BEL concentration dependence of inactivation of an iPLA<sub>2</sub>β mutant protein in which Cys<sup>651</sup> is replaced by Ala<sup>651</sup>. The Cys<sup>651</sup> residue of iPLA<sub>2</sub>β was replaced with Ala<sup>651</sup> by site-directed mutagenesis, and the recombinant iPLA<sub>2</sub>βA<sup>651</sup> mutant protein was expressed in a baculovirus–Sf9 cell system and purified by immobilized metal affinity chromatography in the manner illustrated for native iPLA<sub>2</sub>β in Figure 1. The catalytic activity and sensitivity to inhibition by BEL of iPLA<sub>2</sub>βA<sup>651</sup> (closed bars) and iPLA<sub>2</sub>β (open bars) were then determined as in Figures 1 and 5. Mean values (±SD) are displayed (*n* = 6).

**FIGURE 7.**

MALDI/TOF mass spectra of synthetic cysteine-containing peptides and their BEL-modified products. Synthetic peptides RGPCRAFL (panels A and C) and PRCGVDPVA (panels B and D) were incubated (30 min, 37 °C) with BEL (10  $\mu$ M) in the absence (panels A and B) or presence (panels C and D) of iPLA $_2\beta$  (5  $\mu$ g), and aliquots of the incubation mixtures were analyzed by MALDI/TOF/MS.


**FIGURE 8.**

Tandem mass spectra of BEL-modified, synthetic, cysteine-containing peptides RGPCRAFL and PRCGVDPVA. Panel A is the ESI/MS/MS spectrum produced from CAD of  $[M + 2H]^{2+}$  ( $m/z$  586.80 Da) of peptide RGPCRAFL after incubation with iPLA $\beta$  and BEL, and panel B is the ESI/MS/MS spectrum produced from CAD of  $[M + 2H]^{2+}$  ( $m/z$  583.71 Da) of peptide PRCGVDPVA after incubation with iPLA $\beta$  and BEL. The inset indicates that the mass difference between fragment ions generated before and after the modified cysteine is the residue mass of Cys (103 Da) plus 254 Da.



**FIGURE 9.**

BEL concentration dependence of fractional modification of the synthetic, cysteine-containing peptide PR(C-BEL)GVPDVA. Peptide PRCGVPDVA was incubated (30 min, 37 °C) with various concentrations of BEL and 5  $\mu$ g of iPLA<sub>2</sub> $\beta$ , and the incubation mixture was analyzed by MALDI/TOF/MS. Fractional modification was calculated from intensities of spectral lines for modified and unmodified forms of the peptide. Mean values ( $\pm$ SD) are displayed ( $n = 6$ ).

**FIGURE 10.**


Effect of various concentrations of dithiothreitol (DTT) to protect iPLA<sub>2</sub> $\beta$  from BEL-induced inactivation and alkylation of cysteine residues. Purified, His-tagged iPLA<sub>2</sub> $\beta$  was incubated (37 °C, 10 min) without or with 4  $\mu$ M BEL and various concentrations of DTT, and aliquots were removed for measurement of iPLA<sub>2</sub> $\beta$  activity (panel A) or for tryptic digestion and LC/ESI/MS/MS analyses to identify peptides that contained modified and unmodified cysteine residues at various positions in the sequence (panel B). The fractional modification of various cysteine-containing peptides by BEL was determined by the multiple normalization method and expressed relative to the fraction in a sample without DTT (panel B). Mean values ( $\pm$ SD) are displayed ( $n = 6$ ).

1	11	21	31	41	51	61	71
<b>MQFFGRLVNT</b>	<b>LSSVTNLFSN</b>	<b>PFRVKEVSLA</b>	<b>DYASSERVRE</b>	<b>EGQLILLQNA</b>	<b>SNRTWDCVLV</b>	<b>SPRNPQSGFR</b>	<b>LFQLESEADA</b>
81	91	101	111	121	131	141	151
<b>LVNFQQYSSQ</b>	<b>LPPFYESSVQ</b>	<b>VLHVEVLQHL</b>	<b>TDLIRNHPSW</b>	<b>TVTHLAVELG</b>	<b>IRECFHHSRI</b>	<b>ISCANSTENE</b>	<b>EGCTPLHLAC</b>
161	171	181	191	201	211	221	231
<b>RKGDSEILVE</b>	<b>LVQYCHAQMD</b>	<b>VTDNKGETAF</b>	<b>HYAVQGDNPQ</b>	<b>VLQLLGKNAS</b>	<b>AGLNQVNNQG</b>	<b>LTPLHLACQM</b>	<b>GKQEMVRVLL</b>
241	251	261	271	281	291	301	311
<b>LCNARCNIMG</b>	<b>PGGFPIHTAM</b>	<b>KFSQKGCAEM</b>	<b>IISMSNQIH</b>	<b>SKDPRYGASP</b>	<b>LHWAKNAEMA</b>	<b>RMLLKRGCDV</b>	<b>DSTSASGNTA</b>
321	331	341	351	361	371	381	391
<b>LHAVTRNRF</b>	<b>DCVMVLLTYG</b>	<b>ANAGARGEHG</b>	<b>NTPLHLAMSK</b>	<b>DNMEMVKALI</b>	<b>VFGAEVDTPN</b>	<b>DFGETPAFIA</b>	<b>SKISKQLQDL</b>
401	411	421	431	441	451	461	471
<b>MPVSRARKPA</b>	<b>FILSSMRDEK</b>	<b>RSHDHLLCLD</b>	<b>GGGVKGLVII</b>	<b>QLLIAIEKAS</b>	<b>GVATKDLFDW</b>	<b>VAGTSTGGIL</b>	<b>ALAILHSKSM</b>
481	491	501	511	521	531	541	551
<b>AYMRGVYFRM</b>	<b>KDEVFRGSRP</b>	<b>YESGPLEEFL</b>	<b>KREFGEHTKM</b>	<b>TDVKKPKVML</b>	<b>TGTLSDRQPA</b>	<b>ELHLFRNYDA</b>	<b>PEAVREPRCT</b>
561	571	581	591	601	611	621	631
<b>PNINLKPTQ</b>	<b>PADQLVWRAA</b>	<b>RSSGAAPTIF</b>	<b>RPNGRFLDGG</b>	<b>LLANNPTLDA</b>	<b>MTEIHEYND</b>	<b>MIRKGQGNKV</b>	<b>KKLSIVVSLG</b>
641	651	661	671	681	691	701	711
<b>TGKSPQVPVT</b>	<b>CVDVFRPSNP</b>	<b>WELAKTVFGA</b>	<b>KELGKMVVDG</b>	<b>CTDPDGRAVD</b>	<b>RARAWCEMVG</b>	<b>IQYFRLNPQL</b>	<b>GSDIMLDEVS</b>
721	731	741	751				
<b>DAVLVNALWE</b>	<b>TEVYIYEHRE</b>	<b>EFQKLVQLLL</b>	<b>SP</b>				

**FIGURE 11.**

Amino acid residues in the iPLA<sub>2</sub> $\beta$  sequence identified in MALDI/TOF/MS and/or LC/ESI/MS/MS analyses of BEL-treated iPLA<sub>2</sub> $\beta$  preparations digested with the endoproteases trypsin or Glu-C. Purified, His-tagged iPLA<sub>2</sub> $\beta$  (10  $\mu$ g) was treated (37 °C, 10 min) with BEL (20  $\mu$ M), centrifugally filtered, and digested on-filter with trypsin or Glu-C. Digests were then analyzed by MALDI/TOF/MS and LC/ESI/MS/MS. Residues contained in peptides identified in LC/ESI/MS/MS analyses are denoted by italicized, bold type. Those identified in MALDI/TOF/MS analyses are denoted by bold, nonitalicized type. Residues that were not identified are denoted by plain type.



**Scheme 1.**

Scheme for Modification of Cysteine Residues by iPLA<sub>2</sub>β-Catalyzed BEL Hydrolysis<sup>a</sup>

<sup>a</sup>BEL is hydrolyzed by iPLA<sub>2</sub>β to yield the bromomethyl keto acid BMKA. BMKA then alkylates the thiol group of cysteine residues by nucleophilic addition to eliminate HBr and form a thioether linkage to an α-keto-substituted carboxylic acid.

Table 1

Relative Quantitation of Peptides <sup>422</sup>SHDHLLCLDGGGVK<sup>435</sup> and <sup>456</sup>DLFDWVAGTSTGGILAILHSK<sup>478</sup> <sup>a</sup>

start AA–end AA	<i>m/z</i>	Charge state	control			BEL treated			ratio	
			intensity	<i>F</i> <sub>422–435</sub>	<i>F</i> <sub>456–478</sub>	intensity	<i>F</i> <sub>422–435</sub>	<i>F</i> <sub>456–478</sub>	<i>N</i> <sub>422–435</sub>	<i>N</i> <sub>456–478</sub>
set of reference internal peptides <sup>582</sup> SSGAAPTYYRPNGR <sup>595</sup> <sup>538</sup> QPAELHLFR <sup>546</sup> <sup>596</sup> FLDGGLLANNPTLDAMTEIHEYNQDMIR <sup>623</sup> <sup>38</sup> VREEGQLILLQNASNR <sup>53</sup> <sup>396</sup> QLQDLMPVSR <sup>405</sup> <sup>7</sup> LVNTLLSSVTNLFNPFRR <sup>23</sup>	740.8	2+	788	0.16	0.62	458	0.18	0.65	1.12	1.05
	555.8	2+	410	0.31	1.20	268	0.31	1.12	1.00	0.93
	1064.39	3+	534	0.24	0.92	396	0.21	0.76	0.88	0.82
	613.99	3+	633	0.20	0.77	476	0.17	0.63	0.87	0.81
	593.74	2+	1190	0.11	0.41	877	0.09	0.34	0.88	0.83
	954.96	2+	584	0.22	0.84	368	0.22	0.81	1.03	0.97
quantitated peptides <sup>422</sup> SHDHLLCLDGGGVK <sup>435</sup>	725.79	2+	126			82			av (N):	0.90
<sup>456</sup> DLFDWVAGTSTGGILAILHSK <sup>478</sup>	795.41	3+	490			299			std EV (N):	0.10

<sup>a</sup> *F*<sub>422–435</sub> (intensity fraction of peptide 422–435 on the internal peptides) is calculated by dividing the intensity of peptide 422–435 by the intensities of internal peptides. *F*<sub>456–478</sub> (intensity fraction of peptide 456–478 on the internal peptides) is calculated by dividing the intensity of peptide 456–478 by the intensities of internal peptides. *N*<sub>422–435</sub> (normalized relative content of peptide 422–435) is calculated by *F*<sub>422–435</sub>(BEL)/*F*<sub>422–435</sub>(control). *N*<sub>456–478</sub> (normalized relative content of peptide 456–478) is calculated by *F*<sub>456–478</sub>(BEL)/*F*<sub>456–478</sub>(control).

Table 2

BEL-Modified Peptides Identified by MS and MS/MS Analyses

MW		Δ mass	AA		miss	AA sequence	μM						
theoretical	detected		start	end			0	0.5	1	2	5	10	20
1175.59	1429.83	254.24	54	63	0	(R)TWDCVLVSPR(N)	-	-	-	-	+	+	+
915.39	1169.41	254.02	133	139	0	(R)ECFHHSR(I) <sup>d</sup>	-	+	+	+	+	+	+
2359.06	2613.21	254.15	140	161	0	(R)IISCANSTENEEGCTPLHLACR(K)	-	-	+	+	+	+	+
2607.21			163	185	0	(K)GDSEILVELVQYCHAQMDVTDNK	mis	mis	mis	mis	mis	mis	mis
						(G)							
2579.28	2834.51	254.23	208	232	0	(K)	-	-	+	+	+	+	+
						NASAGLNQVNNQGLTPLHLACQMCK							
						(Q)							
901.53	1155.77	254.24	238	245	0	(R)VLLLCNAR(C)	-	+	+	+	+	+	+
2164.05	2418.4	254.35	246	265	0	(R)CNIMGPGFPHTAMKFSQK(F)	-	-	-	-	-	-	-
1863.84	2118.13	254.29	266	282	0	(K)GCAEMIISMDSNQIHSK(D)	-	-	+	+	+	+	+
2060.96	2314.96	254.00	307	327	0	(R)GCDVDSTASGNTALHVAVTR(N)	-	-	+	+	+	+	+
2071.02	2324.97	253.95	328	346	1	(R)NRFDCVMVLLTYGANAGAR(G)	-	-	-	+	+	+	+
1450.71	1450.58	-0.13	422	435	0	(R)SHDHLLCLDGGGVK(G)	-	-	-	-	-	-	-
2291.20	2545.35	254.15	559	578	0	(R)CTPNINLKPTQPADQLVWR(A)	-	-	-	-	-	-	-
2469.26	2723.56	254.30	644	665	0	(K)SPQVPVTCVDVFRPSNPWELAK(T)	-	+	+	+	+	+	+
1308.52	1308.51	0.01	676	687	0	(K)MVVDCCTDPDGR(A)	D	D	D	D	D	D	D
1502.69	1756.82	254.13	694	705	0	(R)AWCEMVGIQYFR(L)	-	-	-	-	-	-	-

<sup>a</sup>Indicates the peptide was identified by MALDI/TOF only. Mis indicates the peptide was not detected either by MALDI/TOF or by Q-TOF. D denotes an internally disulfide-linked peptide. AA denotes amino acid. Miss denotes a missed cleavage site. MW denotes molecular weight. C denotes a non-BEL-modified cysteine.